Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amaretto: mRNA anti-MESO CAR-T in Advanced Solid Tumors
NCT04981691Phase 1Unknown
- Sponsor
- Ruijin Hospital
- Start
- Oct 2021
- Primary completion
- Jan 2022
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-mesothelin CAR-T cells in solid tumor, pancreatic cancer (PC), ovarian cancer and 3 more, sponsored by Ruijin Hospital. Primary endpoints: Treatment-Emergent Adverse Events at 4 weeks, Treatment-Related Adverse Events at 4 weeks and 2 more. Status: unknown.
02
Drugs
anti-mesothelin CAR-T cells
03
Conditions
solid tumorpancreatic cancer (PC)ovarian cancermalignant mesotheliomagastric cancer (GC)
Beyond the preview
Go deeper on NCT04981691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04981691.